	US 12,134,777 B2
	Alphavirus replicon vector and immunotherapy by administering same
Wataru Akahata, Kensington, MD (US); and Jonathan F. Smith, Redwood City, CA (US)
Assigned to VLP Therapeutics, Inc., Wilmington, DE (US)
Filed by VLP Therapeutics, Inc., Wilmington, DE (US)
Filed on Apr. 28, 2021, as Appl. No. 17/242,916.
Claims priority of provisional application 63/017,993, filed on Apr. 30, 2020.
Prior Publication US 2021/0340567 A1, Nov. 4, 2021
Int. Cl. C12N 15/86 (2006.01); A61K 9/48 (2006.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); A61K 38/00 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 9/4825 (2013.01); A61K 9/5123 (2013.01); A61P 35/00 (2018.01); C07K 14/5434 (2013.01); A61K 38/00 (2013.01); C12N 2770/36143 (2013.01)]

17 Claims

1. A composition comprising

(i) a pharmaceutically acceptable carrier, and

(ii) an alphavirus replicon vector comprising a polynucleotide which encodes (i) alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4, and (ii) a polypeptide comprising a cytokine,

wherein the pharmaceutically acceptable carrier is a delivery vehicle and the alphavirus replicon vector is encapsulated in the delivery vehicle.